Sessions:
February 12, 2026 – 10:00-11:00am JST
April 28, 2026 – 10:00-11:00am EST/3:00-4:00pm GMT
Services: QSP Consulting Service
Products: Certara IQ™
Overview
Certara IQ™ is the industry-leading AI-powered Quantitative Systems Pharmacology (QSP) modeling platform, transforming drug development by making QSP modeling accessible, scalable, and predictive for organizations worldwide. By combining AI-driven modeling, cloud computing, and pre-validated model libraries, it delivers high-confidence predictions—accelerating decision-making across the entire drug development pipeline.
Why attend?
Get an exclusive look at how Certara IQ is reshaping drug discovery and development, bringing QSP modeling to the forefront of precision medicine. Learn how this cutting-edge platform is already powering hundreds of research projects and regulatory submissions, making complex modeling more accessible, efficient, and actionable.
Key takeaways
- AI + Cloud-Powered QSP: See how Certara IQ integrates AI and cloud computing to run faster simulations and generate reliable insights.
- Pre-Validated Model Libraries: Certara IQ includes a repository of validated, well-documented models across therapeutic areas. These models provide powerful starting points for new projects, reducing duplication and accelerating timelines.
- User-Friendly Collaboration: Discover the platform’s intuitive interface, designed to reduce programming barriers and enhance team efficiency.
- Live Expert Insights: Hear from Josh Apgar, Certara’s QSP expert, and participate in a live Q&A to get your questions answered.
Register now
Joshua Apgar, PhD
VP, Head of QSP SoftwareBefore co-founding Applied BioMath, Josh was a Principal Scientist in the Systems Biology Group of the Department of Immunology and Inflammation at Boehringer Ingelheim Pharmaceuticals. His work leveraged physics-based models to: translate in vitro and in vivo data, assess target feasibility, understand drug mechanism of action, and predict human doses. The ultimate goal of this work was to reduce late stage attrition in drug development through a deep and quantitative interrogation of drug pharmacology and disease pathophysiology.
Josh received his PhD from MIT in Biological Engineering where he worked on experiment design for Systems Biology, focusing on the identification of tractable experiments that could allow for the estimation of unknown parameters and reveal complex mechanisms in signal transduction networks. Before that Josh worked at Avaki to develop a highly scalable software platform to support High Performance Computing, and Enterprise Information Integration in the Life Sciences, and Engineering.
Register now
